Business Wire

FlexCat™ by Unifrax Produces Increased Yield with Less Coking in Model PDH Study

27.7.2021 14:00:00 EEST | Business Wire | Press release

Share

Unifrax, a leading manufacturer of high-performance specialty materials, today announced initial results of the first phase of its testing campaign, performed at hte GmbH, leading provider of high throughput technology in catalysis research. These results support the ability of the recently launched FlexCat™ by Unifrax to significantly improve production throughput, increase process runtime and reduce a company’s carbon footprint.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005241/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FlexCat™ by Unifrax PDH testing results in partnership with hte GmbH. (Graphic: Business Wire)

FlexCat, a new customizable fiber-based catalyst support material, is designed for use in industrial catalysis, improving the output of hydrogen and specialty gas production, chemical processing, air purification and other chemical manufacturing applications.

Tested by hte GmbH, Unifrax targeted a model reaction of propane dehydrogenation (PDH) as a common industrial process and compared FlexCat to a literature derived and pellet-supported catalyst. Unifrax’s first step into industrial catalysis is a catalyst support material that has been proven to:

Provide enhanced yield and selectivity.

  • FlexCat increased output by 20 percent in the initial cycle and retained at least 90 percent conversion activity during the subsequent cycle tested.
  • This patented technology provided more tortuosity, maximizing catalyst interaction and producing 50 percent less side products per cycle, including four times less benzene.

Reduce production downtime.

  • FlexCat retained its conversion activity throughout the two cycles, offering up to 50 percent reduction in regeneration time and up to 12 percent longer run time.
  • FlexCat’s innovative product forms can be up to 10 times lighter than the conventional support being used, reducing loading and unloading time.

Allow for reduced downstream processing and cleaner outputs through plant optimization.

  • First lab scale data showed the potential of FlexCat to significantly reduce coking, improve conversion, and increase selectivity; addressing emissions concerns and providing a safer environment for employees and surrounding communities.

“In this latest round of testing, we homed in on specific areas where our industry partners strive to see improvements and derive value – from increased yield, reduced emissions and lower carbon footprints,” said Chad Cannan, senior vice president of research and development, Unifrax. “This next generation of catalysis technology will significantly increase production through existing assets and avoid costly capital expenditures and unnecessary downtime. This data shows that companies can realize greater value through their current production systems and improve their environmental footprint.”

“This collection of data, in partnership with hte GmbH, is a step in the right direction for industrial catalysis,” said John Dandolph, president and CEO, Unifrax. “With FlexCat, we’re working to optimize plant performance and the impact on local communities, focusing on a unique, game-changing solution. In confirming that we can increase output while reducing emissions and overall costs for our industry partners, we are excited to move forward with implementing this new technology to create better and more efficient catalysis that this industry has never seen before.”

With a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, Unifrax has a deep history of fiber-based technology and manufacturing. As a first step into industrial catalysis for Unifrax, FlexCat offers a revolutionary fiber-based catalytic media that delivers more than the alumina-based catalysis technology used today.

“We look forward to continued collaboration with Unifrax on FlexCat,” said Wolfram Stichert, CEO, hte GmbH. “We’ve already seen promising results from our testing, and we can’t wait to see what’s ahead for this exciting and brand-new technology.”

Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. To learn more about FlexCat, visit www.unifrax.com/flexcat.

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn and Facebook.

About hte GmbH

At hte – the high throughput experimentation company, we make R&D in the area of catalysis faster and more productive. We enable cost-effective innovations and reduced time-to-market for new products, thereby allowing our customers in the energy & refining, chemical & petrochemical, and environmental industries to keep ahead of the competition. Our technology and services comprise:

  • R&D Solutions: highly efficient contract research programs at hte’s state-of-the-art laboratories in Heidelberg, Germany.
  • Technology Solutions: integrated hardware and software solutions, enabling our customers to establish high throughput workflows in their own laboratories.

Our customers benefit from broad technical and scientific expertise, exceptional customer orientation, complete end-to-end solutions, and outstanding data quality. Our close ties with BASF guarantee long-term orientation and stability.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Unifrax:
Deborah L. Myers
Global Marketing Communication Director
dmyers@unifrax.com
716.812.4802

For hte GmbH:
Jacqueline Stalica
Marketing Communications Manager
jacqueline.stalica@hte-company.de
+49 (0) 6221 - 74 97 - 290

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye